Core Binding Factor Acute Myeloid Leukemia
Showing 1 - 25 of >10,000
Core Binding Factor Acute Myeloid Leukemia, KIT Mutation-Related Tumors Trial in Suzhou (Avapritinib)
Recruiting
- Core Binding Factor Acute Myeloid Leukemia
- KIT Mutation-Related Tumors
-
Suzhou, Jiangsu, ChinaFirst Affiliated Hospital of Soochow University
Apr 7, 2023
Core Binding Factor Acute Myeloid Leukemia Trial in Guangzhou (Sorafenib, Idarubicin, Cytarabine)
Recruiting
- Core Binding Factor Acute Myeloid Leukemia
- Sorafenib
- +2 more
-
Guangzhou, Guangdong, ChinaDepartment of Hematology,Nanfang Hospital, Southern Medical Univ
May 31, 2022
Core Binding Factor Acute Myeloid Leukemia (CBF-AML) Trial in Milano (Midostaurin)
Recruiting
- Core Binding Factor Acute Myeloid Leukemia (CBF-AML)
-
Milano, ItalyOspedale Cà Granda - Niguarda S.C: Ematologia
Jan 22, 2022
Acute Myeloid Leukemia, Core-Binding Factor Trial in Shanghai (Fludarabine, Cytarabine)
Recruiting
- Acute Myeloid Leukemia
- Core-Binding Factor
-
Shanghai, Shanghai, ChinaXianmin Song
May 5, 2022
Multicenter Retrospective Observatory of Acute Myeloid Leukemia
Recruiting
- Acute Myeloblastic Leukemia Core Binding Factor
- NOT PROVIDED
-
Amiens, France
- +25 more
Sep 27, 2021
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With
Acute Myeloid Leukemia (AML) Trial in Austria, Germany (Dasatinib, Cytarabine, Daunorubicin)
Active, not recruiting
- Acute Myeloid Leukemia (AML)
- Dasatinib
- +3 more
-
Innsbruck, Austria
- +53 more
Sep 19, 2022
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute
Recruiting
- Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- +9 more
- Cytarabine
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Oct 27, 2021
Refractory/Relapse Acute Myeloid Leukemia Trial in Kunming (Venetoclax)
Recruiting
- Refractory/Relapse Acute Myeloid Leukemia
-
Kunming, Yunnan, ChinaDepartment of Hematology,920th Hospital of Joint Logistic Suppor
Mar 28, 2023
Relapsed or Refractory Acute Myeloid Leukemia Trial in Taiyuan (Selinexor, Homoharringtonine, Daunorubicin)
Recruiting
- Relapsed or Refractory Acute Myeloid Leukemia
- Selinexor
- +5 more
-
Taiyuan, Shanxi, ChinaTao Wang
Feb 9, 2023
Acute Myeloid Leukemia Trial in Nanjing (Venclexta 100 MG Oral Tablet)
Recruiting
- Acute Myeloid Leukemia
- Venclexta 100 MG Oral Tablet
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Jun 11, 2023
Acute Myeloid Leukemia Trial in Beijing (Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte
Recruiting
- Acute Myeloid Leukemia
- Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
- "3+7"
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Sep 29, 2023
Relapsed/Refractory Acute Myeloid Leukemia Trial in Beijing
Recruiting
- Relapsed/Refractory Acute Myeloid Leukemia
- Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
- Best-Available Therapy(BAT) Regimen
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Oct 10, 2023
Acute Myeloid Leukemia, Myeloid Tumor Trial in Seattle (Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy)
Not yet recruiting
- Acute Myeloid Leukemia
- Myeloid Neoplasm
- Biospecimen Collection
- +9 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 5, 2023
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia Trial in Seattle (Cladribine, Cytarabine,
Recruiting
- Acute Biphenotypic Leukemia
- +11 more
- Cladribine
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 18, 2022
Secondary Acute Myeloid Leukemia Trial in Ann Arbor (Venetoclax, FLAG Protocol)
Not yet recruiting
- Secondary Acute Myeloid Leukemia
- Venetoclax
- FLAG Protocol
-
Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
Mar 22, 2023
Relapsed Adult AML, Refractory AML Trial in Milwaukee (Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level
Not yet recruiting
- Relapsed Adult AML
- Refractory AML
- Navitoclax Dose Level -1
- +10 more
-
Milwaukee, WisconsinFroedtert Hospital & the Medical College of Wisconsin
Aug 17, 2023
Acute Myeloid Leukemia Trial in Seattle (drug, biological, other)
Active, not recruiting
- Acute Myeloid Leukemia
- Cladribine
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 10, 2022
Acute Myeloid Leukemia Trial in Shenyang (rhTPO, Decitabine)
Recruiting
- Acute Myeloid Leukemia
-
Shenyang, Liaoning, ChinaShengJing Hospital of China Medical University
May 16, 2022
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte (procedure, biological, drug,
Recruiting
- Acute Lymphoblastic Leukemia
- +3 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 12, 2023
Acute Myeloid Leukemia Trial in Shenyang (rhTPO)
Recruiting
- Acute Myeloid Leukemia
-
Shenyang, Liaoning, ChinaShengJing Hospital of China Medical University
Feb 17, 2022
Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Myeloid Tumor Trial in Seattle (drug, biological, other)
Completed
- Acute Leukemia of Ambiguous Lineage
- +2 more
- Cladribine
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Feb 23, 2022
MDS, de Novo, MDS, Secondary, MDS, Previously Treated Trial in Boston (Venetoclax, Azacitidine, Cytarabine)
Recruiting
- Myelodysplastic Syndromes, de Novo
- +10 more
- Venetoclax
- +10 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 23, 2023
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid
Recruiting
- Acute Lymphoblastic Leukemia in Remission
- +11 more
- Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
- +8 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 24, 2022